SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community is currently polarized, caught between frustration over stagnant price action and excitement regarding Ripple's recent treasury platform integration with SWIFT. While some investors are bracing for further volatility and potential token supply unlocks, others are doubling down on long-term conviction, pointing to pending regulatory developments as the potential catalyst for institutional adoption.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and community debate as investors weigh the company's aggressive expansion and strong sales against concerns regarding its high valuation and inflationary pressures. Market participants are intensely focused on upcoming earnings, with active discussions split between bullish expectations for the brand's long-term growth and bearish caution over current price multiples.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In February 2025, Hims &amp; Hers announced the acquisition of a peptide facility in California to meet the growing demand among Americans for personalized healthcare and treatment options.</li><li>An NYT report stated that top leaders at the FDA have reservations about peptides, according to a senior Department of Health and Human Services official.</li><li>On a recent episode of the Joe Rogan podcast, Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA, said he is a “big fan” of peptides.</li></ul>Hims &amp; Hers Health Inc. (HIMS) shares surged on Tuesday morning amid a report stating that the U.S. Food and Drug Administration is moving to lift restrictions on peptides.According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/03/31/health/peptide-ban-fda-rfk-jr.html">report</a> by The New York Times, the FDA is moving to allow compounding pharmacies to manufacture over a dozen injectable peptides&nbsp;that were previously banned due to potential safety risks.This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.<a href="https://stocktwits.com/symbol/HIMS">Shares of Hims &amp; Hers</a>, which provides compounded medications, surged more than 7% in Tuesday morning’s trade.<h2 class="st-heading-2">Top FDA Leaders Have Reservations About Peptides, Says Report</h2>The report added that top leaders at the FDA have reservations about peptides, according to a senior Department of Health and Human Services official. It noted that if the FDA had flagged peptides as being marketed through unproven claims of disease-fighting and cosmetic benefits.In its 2023 notification, the regulator listed several bulk drug substances, including peptides, noting that it had identified “potential significant safety risks” associated with them.<h2 class="st-heading-2">RFK Jr. Says He Is A ‘Big Fan’ Of Peptides</h2>During an episode of the Joe Rogan podcast earlier this month, Secretary of Health and Human Services Robert F. Kennedy Jr. said that he is a “big fan” of peptides. As the HHS secretary, RFK Jr. oversees the FDA.“I’ve used them myself, and used them with really good effect on a couple of injuries,” he said, while adding that during the Biden administration, 19 peptides were “illegally” moved to Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.This category prohibits compounding pharmacies from formulating compounds comprising peptides, RFK Jr. added.“There was huge demand for peptides and a black market came up, and the black market is run by companies that say the peptides are for animal use or research purposes. And that peptide now basically completely replaced the legal market,” he said.<h2 class="st-heading-2">Where Does Hims &amp; Hers Fit In This Case?</h2>Hims &amp; Hers had come&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">under fire</a> from regulators and Novo Nordisk AS (NVO) for offering a compounded version of the company’s best-selling weight-loss pill, Wegovy.Novo Nordisk subsequently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> its lawsuit against Hims &amp; Hers and announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Earlier in February 2025, Hims &amp; Hers announced the acquisition of a peptide facility based in California to address the growing demand from Americans for personalized healthcare and treatment options.“The peptide capabilities made possible through this acquisition position the company in the coming years to explore exciting advances in peptide innovation, including across areas of consumer need such as preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistance,” the company said.<h2 class="st-heading-2">What Are Peptides?</h2>Peptides are short chains of amino acids, the same building blocks that make up proteins, linked together by peptide bonds.Blockbuster weight-loss drugs Ozempic and Wegovy are also peptide medications that use glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity by&nbsp;stimulating insulin secretion.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 39% year-to-date and 33% over the past 12 months. The iShares Core S&amp;P Mid-Cap ETF (IJH) is up 14% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 22%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-sold-apple-shares-too-soon-berkshire/cZEPvVFRIVi">Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides

This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.

Equity

<ul class="summary-bullets"><li>The net proceeds to be received from the sale of common stock offered by the company will be used for general corporate purposes, among other things.&nbsp;</li><li>Avis operates as a vehicle rental operator in North America, Europe, Australasia and other regions, with an average rental fleet of approximately 684,000 vehicles in 2025.&nbsp;</li><li>Morgan Stanley earlier in the month lowered the firm's price target on Avis Budget to $97 from $142 and kept an ‘Equal Weight’ rating on the shares.</li></ul>Avis Budget Group (CAR) shares fell as much as 4% in Friday’s extended hours of trading after the&nbsp;vehicle sharing and rental services provider announced an automatic offering of its common shares.&nbsp;The company is selling its common shares via automatic offering with par value $0.01 per share.The&nbsp;company said that&nbsp;net proceeds from the offering&nbsp;would be used for general corporate purposes, including repayment of indebtedness, acquisitions, additions to working capital, repurchases of common stock, dividends, capital expenditures and investments in the company’s subsidiaries.&nbsp;Net proceeds may be temporarily invested prior to use, the company added.&nbsp;Avis Budget said that to facilitate the offering of the common stock, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of its common stock.&nbsp;<h2 class="st-heading-2">About Avis</h2>Avis operates three globally recognized brands in mobility solutions named as Avis, Budget and Zipcar. It operates as a vehicle rental operator in North America, Europe, Australasia and other regions, with an average rental fleet of approximately 684,000 vehicles in 2025.&nbsp;<h2 class="st-heading-2">Recent Analyst Actions</h2>Morgan Stanley earlier in the month lowered the firm's price target on Avis Budget to $97 from $142 and kept an ‘Equal Weight’ rating on the shares. The firm updated its rental car estimates post Q4, lowering its targets for Avis after what it called "much weaker than expected results and guidance."Deutsche Bank also lowered the firm's price target on Avis Budget to $128 from $148 and kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around CAR trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares of CAR have risen 15% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person views trading stocks on a tablet on the last day of the 2025 trading market in Brussels, Belgium, on December 30, 2025.

Avis Budget Stock Tanks After Hours – What’s Driving It Down?

 The company is selling its common shares via automatic offering with par value $0.01 per share.

<ul class="summary-bullets"><li>Its net sales were $1.104 billion for the fourth quarter, compared to $1.283 billion in the prior year's fourth quarter.</li><li>However, adjusted earnings per share of $0.49 for the fourth quarter ended January 31, 2026, easily surpassed Wall Street consensus of $0.37 as per Stocktwits data.</li></ul>GameStop (<a href="https://stocktwits.com/symbol/GME">GME</a>) shares fell as much as 5% during Tuesday’s extended hours of trading after the video game retailer reported its fourth quarter earnings.&nbsp;The company reported a decline in its fourth quarter net sales. Its net sales were $1.104 billion for the fourth quarter, compared to $1.283 billion in the prior year's fourth quarter. Analysts on average expected net sales of $1.47 billion, according to data from Stocktwits.&nbsp;<h2 class="st-heading-2">More Details</h2>The company posted adjusted earnings per share of $0.49 for the fourth quarter ended January 31, 2026, easily surpassing Wall Street consensus of $0.37 as per Stocktwits data.&nbsp;GME reported operating income of $135.2 million for the fourth quarter, compared to $79.8 million in the prior year's fourth quarter.&nbsp;Cash, cash equivalents and marketable securities were $9.0 billion at the close of the quarter compared to $4.8 billion at the close of the prior year's fourth quarter. GME’s Bitcoin and related receivables were valued at $368.4 million at the close of the quarter.<h2 class="st-heading-2">Full Year&nbsp;</h2>The company posted net sales of $3.630 billion for fiscal year 2025, compared to $3.823 billion in fiscal year 2024.&nbsp;GME posted an operating income of $232.1 million for the year, compared to an operating loss of $26.2 million in fiscal year 2024. Its net income was $418.4 million for fiscal year 2025, compared to $131.3 million from the previous year.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around GME trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;A Stocktwits user praised the company's earnings and said that GME "straight up crushed EPS”.&nbsp;<stembedurl>https://stocktwits.com/TheNeighborhoodSancho/message/648442142</stembedurl>Shares in the company have jumped 12.6% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The GameStop logo is being displayed on a smartphone with GameStop visible in the background. (Photo by Jonathan Raa/NurPhoto via Getty Images)

Why Is GameStop Stock Nosediving Today?

The company reported a decline in its fourth quarter net sales that also missed analyst expectations according to data from Stocktwits. 

Should iShares Core S&P Mid-Cap ETF (IJH) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The acquisition is subject to customary closing conditions and certain third-party approvals, including approval by Fannie Mae and Freddie Mac.</li><li>Zions will now be able to offer its clients an expanded product suite through its participation in a variety of important lending programs, including the Fannie Mae DUS program.&nbsp;</li></ul>Zions Bancorp (ZION) on Monday said that it has entered into a definitive agreement to acquire the agency lending business of Basis Multifamily Finance I, LLC, a subsidiary of Basis Investment Group, which includes its experienced team, access to agency lending programs, and all associated mortgage servicing rights.Shares of Zions jumped during extended hours of trading and was up 3% at the time of writing. The acquisition is subject to customary closing conditions and certain third-party approvals, including approval by Fannie Mae and Freddie Mac.&nbsp;The company did not disclose the value of the deal.&nbsp;<h2 class="st-heading-2">Deal Details</h2>In connection with the acquisition, Zions and Basis have entered into a strategic partnership that will expand each respective company's real estate financing and capital formation efforts.“The acquisition of Basis' agency lending business will strategically expand our capabilities to meet the needs of our commercial real estate customers. This is a natural, customer-driven evolution of our capital markets strategy, which continues to be a meaningful growth engine for the company,” said Harris Simmons, Chairman and CEO of Zions Bancorporation.“This transaction is a great result for all stakeholders, enabling the agency platform to scale while driving financing and investment activity across Basis' diversified Funds platform through our ongoing partnership with Zions,” said Tammy K. Jones, CEO and Founder of Basis.By acquiring Basis' agency lending business, Zions will be able to offer its clients an expanded product suite through its participation in a variety of important lending programs, including the Fannie Mae DUS program, and the Freddie Mac Optigo Conventional and Small Balance Loan programs.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around ZION trended in ‘neutral’ amid ‘normal’ message volume.&nbsp;Shares in the company have fallen 6% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

US-Dollar banknotes and model of a privately owned house.

Zions Bancorp Stock Is Rising After-Hours – Know Why

Zions and Basis have entered into a strategic partnership that will expand each respective company's real estate financing and capital formation efforts.

Shares of Five Below Inc. (FIVE) jumped 7% after hours on Wednesday after the company reported fourth-quarter (Q4) earnings and revenue numbers above Wall Street expectations, while also dismissing the impact of tariffs on the company’s supply chain going forward.The discount store company, which mostly sells items priced between $1 and $5, now expects FY26 earnings per share in the range of $7.74-$8.25 and revenue of $5.2 billion to $5.3 billion. Wall Street, on average, was expecting revenue of $5.2 billion and earnings per share of $6.96.Same store sales are expected to increase by about 3% to 5% in the period while the company opens about 150 net new stores.<h2 class="st-heading-2">Management Perspective</h2>“Looking ahead, we are focused on delivering trend-right merchandise at exceptional value... With a growing store base, strong new store performance, and a differentiated customer value proposition, we believe we are well positioned to drive sustainable sales growth, margin expansion, and long-term shareholder value.” Winnie Park, CEO of Five Below, said.The company also expressed optimism for tariffs not impacting its supply chain going forward. &nbsp;“...last year we had the tariffs hit us, and so we weren't able to actually buy or attain all the products that we wanted to fill out some of our worlds. This year, that is not an obstacle,” an executive said during the company’s post-earnings call with analysts.Q4 NumbersIn the fourth quarter, same store sales increased by 15.4%, pushing revenue for the period up 24.3% to $1.73 billion. Adjusted earnings for the period came in at $4.31 compared to $3.48 in the corresponding quarter of fiscal 2024, and above an estimated $4, according to data from Fiscal.ai.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FIVE stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘high’.<a href="https://stocktwits.com/symbol/FIVE">FIVE stock</a> has gained 187% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/logi-stock-rises-after-hours-on-1.4-billion-share-buyback-program/cZ37Fl6RIWI">LOGI Stock Rises After Hours On $1.4B Share Buyback Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Logo of the Five Below store in Roseville, Minnesota. Source: : Michael Siluk/UCG/Universal Images Group via Getty Images

FIVE Stock Soars After Upbeat Q4 Results — Here’s What Management Said About Tariff Impact

The discount store company, which mostly sells items priced between $1 and $5, now expects FY26 earnings per share in the range of $7.74-$8.25 and revenue of $5.2-$5.3 billion.

Lantheus Holdings, Inc. (LNTH) said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.Shares of the company slipped marginally after hours at the time of writing.<h2 class="st-heading-2">Why The Delay?</h2>The agency is now slated to decide on the radiopharmaceutical-focused company’s application seeking approval for the diagnostic kit by June 29. The extended deadline is expected to give the agency additional time to review and consider further manufacturing related information submitted by Lantheus, it said.The extension, however, is not related to the efficacy or safety data of LNTH-2501, a radioactive diagnostic kit for for use with positron emission tomography (PET) for detecting somatostatin receptor positive neuroendocrine tumors in adults as well as pediatric patients, the company added.LNTH-2501 is not available in the U.S. yet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNTH stock stayed within the ‘extremely bearish’ territory while message volume fell from ‘high’ to ‘normal’ levels.According to data from Koyfin, the 12-month average price target on the stock is at $91, representing a potential upside of about 13%. Of the 13 analysts covering the stock, 11 rate it ‘Buy’ or higher while two rate it a ‘Hold.’Earlier this month, Lantheus announced that the FDA approved its PYLARIFY TruVu injection. The injection is indicated for imaging certain lesions in men with prostate cancer, the second most common form of cancer affecting men in the U.S. It is now expected to be commercially available in the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/LNTH">LNTH stock</a> has slipped 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lulu-shares-fall-despite-board-reshuffle-as-2026-outlook-misses-street-expectations/cZ3EZeyRIXz">LULU Shares Fall Despite Board Reshuffle As 2026 Outlook Misses Street Expectations</a>Get updates to this developing story directly on Stocktwits.

In this photo illustration, the Lantheus Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application

LNTH Stock - Lantheus Holdings, Inc. (LNTH) said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.

The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.


<ul class="summary-bullets"><li>UiPath will report quarterly results after the markets close on Wednesday.</li><li>Traders are keenly watching high short interest, anticipating a massive squeeze and significant upside potential post-earnings.</li><li>Stocktwits sentiment for PATH jumped to ‘extremely bullish’ from ‘bullish.’</li></ul>Retail sentiment for UiPath, Inc.&nbsp;on Stocktwits climbed sharply higher even as the stock broke its five-day winning streak on Tuesday, ahead of its fourth-quarter report.&nbsp;The retail trading community on the platform believes that rising short positions pressured PATH stock, although many expect a strong earnings report on Wednesday, which could prompt a short squeeze. A short squeeze occurs when a heavily shorted stock rises sharply, forcing short sellers to buy back shares and pushing the price even higher.&nbsp;UiPath is among the key stocks investors are watching amid rising enterprise adoption of AI tools. The company offers software that automates repetitive, time-consuming business tasks, such as filling out forms, extracting information from documents, and generating reports – also known as Robotic Process Automation (RPA).&nbsp;Over the past year, it has doubled down on its shift to AI-driven, agentic automation, rolling out new tools such as Agent Builder and deepening partnerships with players including OpenAI, SAP, and Deloitte.PATH Stock Move<a href="https://stocktwits.com/symbol/PATH">UiPath shares</a> dropped 3.2% on Tuesday, though they recouped part of the loss in the after-hours session. They’ve been on a sharp upward trajectory, rising by over 16% over the past nine sessions, though they are still down about 30% year to date.Notably, short interest in shares has risen to a record 15.7% from 7.9% in mid-December, per Koyfin data.&nbsp;<h2 class="st-heading-2">Retail’s View On PATH</h2>Stocktwits sentiment for the stock shifted to ‘extremely bullish’ as of late Tuesday, from ‘bullish’ the previous day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_11_at_7_15_44_AM_png_6aae7641ef.webp" alt="Screenshot 2026-03-11 at 7.15.44 AM.png" width="699" height="85"><figcaption>PATH sentiment and message volume as of March 10 | Source: Stocktwits</figcaption></figure>“For a red day after many green ones, I can not complain, as it was only 3%. Tomorrow is the big day. $15 plus on a good report!”&nbsp;<a href="https://stocktwits.com/TheDizPlinTrader/message/647158950">said</a> a user.Another&nbsp;<a href="https://stocktwits.com/fundamentalCo/message/647091456">said</a>: “60%+ short squeeze with a stellar FY result and improved guidance is completely possible with 20%+ short interest, let’s go!”&nbsp;Some traders held a different view, owing to the same short positions and the news that chip giant Nvidia is reportedly planning to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-s-next-ai-bet-report-says-nemo-claw-could-power-enterprise-ai-agents/cZdoNuERIes">launch an agentic AI platform</a>.&nbsp;“It's very risky and with nvda news out the whole software sector is back to tanking mode and It's a longer term event. Strong sell imo,”&nbsp;<a href="https://stocktwits.com/Darth_Bearius/message/647113437">said</a> a bearish user.<h2 class="st-heading-2">PATH Earnings Watch, Recent Updates</h2>Analysts expect revenue to rise nearly 10% to $464.8 million, per Koyfin, when the company reports its fourth-quarter results after the markets close on Wednesday. Adjusted profit is expected to decline 2% to $0.25 per share.UiPath&nbsp;won a spot in the S&amp;P 400 at the start of the year. Meanwhile, CEO and Chairman Daniel Dines sold over $4 million worth of shares in January 2026 and December 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A UiPath logo seen displayed on a smartphone with stock market percentages in the background. 

PATH Stock Snaps 5-Day Winning Streak — Why Retail Sentiment Is Surging Ahead Of Q4 Earnings

UiPath’s Short interest has climbed to 15.7%, nearly double mid-December levels, prompting some traders to expect a short squeeze if the earnings report beats expectations.

<ul class="summary-bullets"><li>AVAV’s net loss for Q3 of fiscal 2026 was $156.6 million, or $3.15 loss per diluted share, as compared to net loss of $1.8 million, or $0.06 loss per diluted share from the year-ago period.</li><li>The company's third quarter results were impacted by revenue timing and adjustments in its Space business, the CEO said.&nbsp;</li></ul>Aerovironment stock plummeted 8% during after-hours trading on Tuesday after its weak third quarter revenue for fiscal 2026 and&nbsp;widening quarterly loss spurred a selloff in the stock.It reported third quarter revenue of $408.0 million which fell well short of analyst expectations of $475.65 million, as per data from Fiscal.ai.However, revenue increased 143% as compared to $167.6 million for the third quarter of fiscal 2025, due to higher product sales of $138.1 million and higher service revenue of $102.3 million.“While our third quarter results were impacted by revenue timing and adjustments in our Space business, demand for our unique solutions remains robust,” said Wahid Nawabi, AeroVironment chairman, president and chief executive officer.“Strong order flow and growth in funded backlog during the quarter are setting the stage for record fourth quarter revenue and a solid start to fiscal year 2027. We are executing with discipline, scaling manufacturing ahead of demand and accelerating the commercialization of our platforms to improve profitability and time to market,” Nawabi said.&nbsp;<h2 class="st-heading-2">More Details</h2>Net loss for the third quarter of fiscal 2026 was $156.6 million, or $3.15 loss per diluted share, as compared to net loss of $1.8 million, or $0.06 loss per diluted share, in the prior-year period, respectively. The current quarter was negatively impacted by goodwill impairment charges of $151.3 million.&nbsp;In January, the company received a stop-work order on its&nbsp;deal for the delivery of BADGER phased array antenna systems to support Space Force’s Satellite Communication Augmentation Resource (“SCAR”) program.&nbsp;The U.S. Space Force earlier in the month announced that it is putting the Satellite Communications Augmentation Resource program back up for competition, which significantly affected AVAV’s backlog.&nbsp;Gross margin for the third quarter of fiscal 2026 was $98.8 million, an increase of 56% as compared to $63.2 million for the third quarter of fiscal 2025, reflecting higher product margin of $19.1 million and higher service margin of $16.5 million.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around AVAV stock trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 20.3% year-to-date.&nbsp;

AeroVironment exhibited during the Defense Expo Korea 2022, held at KINTEX (Korea International Exhibition and Convention Center) on September 21, 2022 in Goyang city, Gyeonggi, South Korea. 

AVAV Stock Plummets As Q3 Revenue Comes Way Below Wall Street Expectations, Triggering Selloff

It reported third quarter revenue of $408.0 million which fell well short of analyst expectations of $475.65 million, as per data from Fiscal.ai.

<ul class="summary-bullets"><li>MTN reported Q2 fiscal 2026 net income attributable to Vail Resorts of $210.0 million compared to $244.4 million in the prior year.&nbsp;</li><li>Due to the persistent, historically challenging weather conditions in the Rockies, which continued to limit terrain availability, the&nbsp;company&nbsp;is reducing its fiscal 2026 guidance, MTN’s CEO noted.&nbsp;</li><li>The company now expects net income attributable to Vail Resorts of $144 million to $190 million for its FY 2026.&nbsp;</li></ul>Vail Resorts shares fell in extended hours of trading on Monday after its second quarter revenue of its FY 2026 fell compared to the year-ago quarter&nbsp;and missed analysts’ expectations.&nbsp;The company reported total net revenue of $1.08 billion during the reported quarter, down from $1.13 billion it reported year-ago. Analysts, on average, had expected revenue of $1.11 billion, as per from Fiscal.ai data.&nbsp;"This has been the most challenging winter across the Rockies that we have ever experienced with the lowest snowfall levels in more than 30 years for our Colorado and Utah resorts, combined with warmer temperatures, resulting in reduced terrain throughout the quarter and into February,” said Rob Katz, Chief Executive Officer, Vail Resorts.&nbsp;“While these conditions and the resulting visitation headwinds negatively impacted our quarterly results, we remained focused on the areas within our control. This includes our advanced commitment strategy, continued investments in our resorts and our employees, and progressing key initiatives to optimize visitation, including enhanced marketing and new products,” he added.&nbsp;<h2 class="st-heading-2">Q2 2026 Snapshot</h2>Vail Resorts reported Q2 fiscal 2026 net income attributable of $210.0 million compared to $244.4 million in the prior year.&nbsp;Its resort net revenue decreased $53.2 million, or 4.7%, compared to the prior year, which was primarily driven by the unfavorable weather conditions that impacted visitation and ancillary spending for both local and destination guests during the period.<h2 class="st-heading-2">Cuts 2026 Guidance</h2>The company now expects net income attributable to Vail Resorts, Inc. of $144 million to $190 million for its FY 2026.&nbsp;"Due to the persistent, historically challenging weather conditions in the Rockies, which continued to limit terrain availability, the Company is reducing its fiscal 2026 guidance. While we are lowering our estimates for the fiscal year, given the unprecedented weather in the Rockies, the impact from conditions was mitigated by our advance commitment strategy and resource transformation efforts,” Katz said.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around MTN stock trended in ‘bearish’ territory amid ‘extremely high’ message volume.Shares in the company have been flat so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vail Resorts shares fell in extended hours of trading on Monday after its second quarter revenue of its FY 2026

Vail Resorts Earnings And 2026 Guidance Cut Kills Investor Optimism

The company reported total net revenue of $1.08 billion during the reported quarter, down from $1.13 billion it reported year-ago.

iShares Trust - iShares Core S&P Mid-Cap ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

IJH
iShares Core S&P Mid-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IJH News

IJHiShares Core S&P Mid-Cap ETF